Izuma Nakayama
Chiba, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 114 publications
Author's Reply: Neutrophil-Macrophage Interactions in Gastric Cancer.
Journal: Cancer science
Published: July 16, 2026
Prognosis-predicting factor of gastrectomy after systemic cancer therapy for cStage IVB gastric cancer.
Journal: Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
Published: June 13, 2026
EP4 Antagonist ONO-4578 Plus Nivolumab and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Negative Unresectable Advanced or Recurrent Gastric or Gastroesophageal Junction Cancer.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 01, 2026
Spatial organisation of tumor-infiltrating B-cells informs immune checkpoint inhibitor response in Claudin 18.2-expressing gastric cancer.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 27, 2026
Impact of claudin 18.2 expression on the efficacy of trastuzumab deruxtecan in patients with HER2-positive gastric or gastroesophageal junction cancer.
Journal: ESMO gastrointestinal oncology
Published: April 17, 2026
Exploratory analysis of HER2-positive/CLDN18.2-positive metastatic gastric and gastroesophageal junction cancer toward future therapeutic development.
Journal: ESMO gastrointestinal oncology
Published: March 11, 2026
A case of gastritis developing in a patient receiving zolbetuximab-containing chemotherapy for CLDN18.2-positive advanced gastric cancer.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
Temporal dynamics of CLDN18.2 expression following zolbetuximab treatment in advanced gastric cancer.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
An open-label phase Ib/II study of trastuzumab deruxtecan combined with nivolumab and CAPOX for HER2-low gastroesophageal adenocarcinoma.
Journal: ESMO gastrointestinal oncology
Published: February 06, 2026
An evaluation of pembrolizumab with trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for HER2 positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1 (CPS ≥1).
Journal: Expert review of anticancer therapy
Published: February 05, 2026
Targeting claudin 18.2 in gastric cancer: a review of emerging biologic agents.
Journal: Expert opinion on biological therapy
Published: January 16, 2026
Last Updated: 09/26/2026